At Memorial Sloan Kettering, we are committed to learning how to better diagnose, treat, and support people with cancer of unknown primary.

MSK researchers are leading promising new studies to identify therapeutic biomarkers (genetic mutations or other characteristics of a cell that promote tumor growth and may predict its response to treatment).

In conjunction with MSK’s Human Oncology and Pathogenesis Program, our pathologists and medical oncologists are working to better understand how the molecular information obtained from MSK-IMPACT™ and other tests performed by the Department of Pathology can help determine a likely primary site of disease for people with cancer of unknown primary.